AstraZeneca sells European rights to heart drug
It will receive an initial US$200mln followed by a further US$10mln, plus sales-related milestone payments
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 37 of 55
Archive
Apres moi le deluge: Flood of blue chip results to dominate in coming week, including BT Group
Over the five sessions in the Week Ahead, around 20% of the FTSE 100 index will report results or issue a trading update, with about half that number due on Thursday alone
Investments and investor services
FTSE 100: Forget Brexit, here’s what we’ll learn from a bumper earnings week
We have a deluge of earnings statements from some of Britain's biggest businesses. Below we discuss the themes likely to emerge from the mid-term reporting season
Redx Pharma looks for some Porcupine help in its fight against cancer and fibrosis
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
Concepta appoints former CEO of Genedrive as new chairman
The AIM-listed fertility aid manufacturer said Matthew Walls would become chairman with immediate effect, while former chair Adam Reynolds would become a non-executive director
Two of AstraZeneca’s key cancer drugs win speedy approvals in Japan
Lynparza and Imfinzi are likely to play an important role if AstraZeneca is to hit its target of generating annual sales of US$45bn by 2023
AstraZeneca’s Lynparza drug sails through late-stage ovarian cancer study
The drug has already been approved for later use in ovarian and breast cancer patients, but the SOLO-1 trial has sowed it could be useful as a first-line treatment
UBS reckons Tagrisso will be worth more than US$5bn a year to AstraZeneca by 2022
Tagrisso sales look like they will beat expectations over the coming years, but UBS has concerns that the future profits drag brought about by externalisation deals hasn’t been properly factored into estimates yet
AstraZeneca’s pipeline turnaround is “remarkable”, but potential is already priced in
Liberum’s Roger Franklin likes AstraZeneca, but thinks the current share price is fair, given the potential of the pipeline
AstraZeneca and Eli Lilly halt late-stage Alzheimer’s study as drug shows no sign of working
AstraZeneca and Lilly’s lanabecestat drug can be added to the list of failed Alzheimer’s treatments; in fact, 99% of all drugs developed to treat the disease have failed clinical trials in the past ten years
Avacta Group appoints Immunocore’s Eliot Forster as non-executive chairman
The AIM-listed firm said Dr Trevor Nichols, who has acted as chairman of the board since January 2014, will remain on the board as non-executive director
AstraZeneca and Merck present data from prostate cancer trial at ASCO 2018
The data showed that the combination of Lynparza and abiraterone can help patients with a specific form of prostate cancer to live for longer without their disease getting worse
AstraZeneca chalks up another phase III fail as COPD drug misses target
Chief medical officer Dr Sean Bohen called the result disappointing
AstraZeneca receives more solid data for its Imfinzi lung cancer treatment
Imfinzi showed a “statically-significant” benefit to overall survival in patients with unresectable stage III non-small cell lung cancer
Third time lucky for AstraZeneca and its Lokelma hyperkalaemia treatment
The US Food and Drug Administration had twice rejected AstraZeneca’s applications for Lokelma due to issues at the manufacturing plant in Texas
Investments and investor services
FTSE 100 propelled to new record close as pound weakens and Dow Jones breaches 25,000
FTSE 100 reached a new record close on Monday after achieving it last time on Thursday
AstraZeneca disappoints with Q1 sales but ‘remains on track’ to hit full-year growth guidance
The FTSE 100-drugs giant expects product sales, which have been in decline for a while now, to return to growth this year
FTSE 100 closes lower, off record peak; Glencore top loser
Footsie closed around nine points at 7,778 but it was still up 0.70% on the week - its eighth weekly gain in a row.
Archive
It’s all about the drugs: AstraZeneca Q1 results will be Friday’s main focus
The day ahead includes first-quarter numbers from both blue-chip drugmaker AstraZeneca PLC and mid-cap generics firm Hikma Pharmaceuticals PLC
FTSE 100 closes in red as there is little around to spark investor interest
FTSE 250 fared better though closing ahead by around 15 points at 20,800.